Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRICORDA: Triple Therapy vs High Dose ICS/LABA in T2-high Asthma
NCT05919394Phase 4Withdrawn
- Sponsor
- Empírica
- Start
- Jun 2023
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in asthma (2 arms), sponsored by Empírica. Primary endpoint: Percentage of patients controlled at 52 weeks. Planned start Jun 2023; status: withdrawn.
02
Conditions
asthma
Beyond the preview
Go deeper on NCT05919394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919394.